Last updated: April 24, 2026
Who Supplies Degarelix Acetate for Pharmaceutical Manufacturing?
Degarelix acetate is a gonadotropin-releasing hormone (GnRH) antagonist used in oncology. Industrial supply typically splits across (1) API manufacturers that make degarelix acetate (or degarelix substance then convert to the acetate salt), and (2) contract manufacturers that formulate and package the final sterile drug product. The operative supply chain is constrained by regulatory status (DMF/CEP/marketing authorization pathways), injectable sterility requirements, and the small number of qualified suppliers for a mature oncology peptide.
Which Supplier Categories Matter for Degarelix Acetate?
1) API (active pharmaceutical ingredient) makers
These firms supply degarelix acetate as:
- A “degarelix substance” followed by controlled salt formation to acetate, or
- Degarelix acetate directly under cGMP with a drug master file (DMF) or equivalent dossier package.
2) Sterile injectables CDMOs
These firms produce finished dosage forms (commonly vial-based lyophilized or solution depending on the origin product) under:
- Injectable sterile manufacturing controls,
- Freeze-drying and vial/stopper handling controls (if lyophilized),
- Quality systems aligned to EMA/FDA expectations.
3) Salt-form / peptide manufacturing specialists
For peptides, suppliers often sit in one of two roles:
- Peptide synthesis and purification (solid-phase peptide synthesis and orthogonal purification),
- Salt formation and crystallization/conditioning into the acetate form.
What Product Form and Regulatory Status Typically Drive Supplier Selection?
Degarelix acetate is used as a therapeutic peptide injection. Supplier qualification generally depends on whether the supply is structured to support:
- Generic or authorized-duplicate pathways (ANDA/MAA),
- Authorized supply into branded oncology markets,
- Compatibility with peptide stability and sterile fill-finish.
The practical supplier short list is usually those with:
- Demonstrated experience with injectable peptide APIs and/or sterile peptide drug products,
- Established regulatory dossier footprint (DMF for API and/or DMF references for fill-finish).
Supplier Data: What’s Available in Public Patent/Regulatory Signals?
No complete, authoritative supplier roster can be produced from the information provided. The identity of current commercial suppliers of degarelix acetate varies by:
- Territory and channel (direct to pharma vs through distributors),
- Whether the supplier provides API only or full sterile drug product,
- Year-specific qualification cycles.
Because supplier lists for a specific, regulated peptide API are not consistently enumerated in a single public source, producing a complete and accurate “suppliers for DEGARELIX ACETATE” table without verified dossier or regulatory references would risk publishing incorrect supplier names.
Supply Chain Reality for Degarelix Acetate (What Bidders Actually Need to Verify)
Even when procurement teams believe they know the supplier, the due diligence checklist that determines “real supply capability” usually includes:
- CIP/DMF coverage: whether degarelix acetate is covered by an FDA DMF (API) or an EMA dossier reference (CEP or equivalent), and whether it is lettered to customers.
- Sterile manufacturing linkage: if the target is finished dose supply, whether the sterile fill-finish site has peptide handling and validated sterile processes.
- Salt form control: confirmation of acetate form control and specifications for identity, assay, water, and polymorphic or crystallinity-relevant attributes.
- Stability and storage: whether the supplier provides stability protocols and data aligned with label storage conditions for sterile injectable products.
- Capacity and lead times: whether peptide API synthesis and sterile manufacturing are supply-constrained (common for mature oncology peptides).
Key Takeaways
- Degarelix acetate supply is concentrated among a limited set of API makers and sterile injectable CDMOs with peptide-specific manufacturing controls and regulatory dossier coverage.
- A correct “supplier list” requires verified regulatory dossier references and/or marketing authorization supply-chain linkage; supplier identity varies by product form (API vs finished injectable) and by geography.
- Procurement qualification should prioritize DMF/dossier coverage, salt-form control to acetate, and validated sterile peptide fill-finish capabilities.
FAQs
-
Is degarelix acetate always supplied as the acetate salt, or is it formed during manufacturing?
It can be supplied as degarelix acetate directly or as degarelix substance with subsequent controlled salt formation, depending on the supplier’s process and dossier.
-
Do API suppliers also provide the sterile injectable finished product?
Often no. Many suppliers provide API only, while separate CDMOs handle sterile manufacturing and packaging.
-
Why do supplier lists differ by country?
Regulatory approval, dossier references, and commercial agreements differ by market, so the qualified supplier set can shift by territory.
-
What is the most important qualification document for an API supplier?
For FDA pathways, an API DMF and its letter of authorization status are critical; for EMA pathways, dossier references or equivalent documentation are used.
-
What manufacturing capability is most difficult for peptides like degarelix?
Maintaining peptide quality through synthesis and purification, and then controlling sterile injectable fill-finish conditions, is often the primary bottleneck.
References (APA)
[1] U.S. Food and Drug Administration. (n.d.). Drug Master File (DMF) and related regulatory guidance. FDA. https://www.fda.gov/drugs/drug-master-files-dmfs
